About Spotlight Therapeutics
Spotlight Therapeutics is a company based in Hayward (United States) founded in 2017. Spotlight Therapeutics has raised $80.67 million across 5 funding rounds from investors including HHS, EPIQ and GordonMD Global Investments. The company has 32 employees. Spotlight Therapeutics operates in a competitive market with competitors including Senti Biosciences, Beam Therapeutics, eGenesis, Annexon and TScan Therapeutics, among others.
- Headquarter Hayward, United States
- Employees 32
- SectorsHealthcare
- Email••••••••
- Website spotlighttx.com
- Social LinkedIn
- Legal Name Spotlight Therapeutics Inc
- Total Equity Funding$80.67M (USD)
in 5 rounds
- Latest Funding Round$533.94K (USD), Grant
Sep 2023
- InvestorsHHS
& 5 more
- Employee Count32
Funding Insights of Spotlight Therapeutics
Spotlight Therapeutics has successfully raised a total of $80.67M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $533.94 thousand completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $80.67M
- Total Rounds 5
- Last Round Grant — $533,939
- First Round $7.27M
(Jan 2018)
- Investors Count 6
All 5 funding rounds of Spotlight Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2023 | $533,939 | Grant | – | – | |
| Mar 2022 | $36.5M | Series B | – | GordonMD Global Investments, EPIQ | |
| Nov 2020 | $30M | Series A | – | Google Ventures | – |
| Sep 2019 | $6.9M | Series A | – | – | – |
| Jan 2018 | $7.27M | Series A | – | – | – |
6 investors in total: 6 institutional.
Investors in Spotlight Therapeutics
Spotlight Therapeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, EPIQ and GordonMD Global Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment management services are provided in the biopharmaceutical sector. | 2021 | gordonmdglobalinvestment.com | Beverly Hills, United States | |
Diversified asset management services are offered by EPIQ. | 2018 | epiqcg.com | San Francisco, United States | |
Magnetic Ventures is focused on transforming healthcare through AI and biotech investments. | 2018 | magneticvc.com | - | |
Corporate backed venture capital fund investing in multiple sectors | – | gv.com | Mountain View, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
- | – | emersoncollective.com | - |
Investor details for Spotlight Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Spotlight Therapeutics
24 people are tracked at Spotlight Therapeutics (4 in leadership, 9 in board & advisors, 11 in team); the tracked headcount is 32.
| Name | Role | Group |
|---|---|---|
Mary Haak-Frendscho | President & CEO | Leadership |
Adam Silverman | VP, Protein Sciences | Leadership |
Cheng Li | VP, Business & Corporate Development | Leadership |
Jack Walleshauser | Senior Scientist, Head Of Analytics | Leadership |
Patrick Hsu | Founder & Scientific Advisor | Board & advisors |
Krishna Yeshwant | Board Member | Board & advisors |
Craig Gordon | Board Member | Board & advisors |
Ron Levy | Scientific Advisor | Board & advisors |
Jennifer Altman | Board Member | Board & advisors |
Alex Marson | Founder, Board Member & Advisor | Board & advisors |
Jacob Corn | Founder & Scientific Advisor | Board & advisors |
Carolyn Bertozzi | Scientific Advisor | Board & advisors |
Jim Wells | Scientific Advisor | Board & advisors |
Ashil Bans | Senior Research Assistant | Team |
Kory Melton | Research Associate III | Team |
Weng In Leong | Senior Scientist | Team |
Radwan Kiwan | Scientist | Team |
Peter Otoupal | Scientist II | Team |
Prachi Prakash Khekare | Research Assistant 2 | Team |
Shannon McCawley | Senior Research Associate | Team |
4 more people are available in the full profile.
Complete people profiles for Spotlight Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Spotlight Therapeutics
3 dated milestones of Spotlight Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Spotlight Therapeutics is founded.
- Funding First funding round of $7.3M.
- Funding Latest funding round, Grant, of $534K.
Competitors of Spotlight Therapeutics
Spotlight Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Senti Biosciences, Beam Therapeutics, eGenesis, Annexon and TScan Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sentibio.com | 2016 | San Francisco, United States | $158M | – | Cell-based therapies for cancer treatment are developed. | |
| beamtx.com | 2017 | Cambridge, United States | $222M | 340 | Developer of gene therapy using CRISPR base editing to treat diseases | |
| egenesisbio.com | 2015 | Cambridge, United States | $481.42M | 94 | Gene transplantation platform for humanizing pig cells is developed. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. | |
| lyell.com | 2018 | San Francisco, United States | $493M | 224 | CAR-T and TIL immunotherapies for solid tumors are developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| hummingbirdbioscience.com | 2015 | Singapore | $150M | – | Antibody drugs for cancer treatment are developed. | |
| aldeyra.com | 2004 | Lexington, United States | $4.79M | 30 | Drug candidates for immune-mediated diseases are developed by Aldeyra. |
Detailed competitors of Spotlight Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Spotlight Therapeutics
Complete news archive for Spotlight Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Spotlight Therapeutics
10 companies that operate in the same segment as Spotlight Therapeutics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Spotlight Therapeutics
Spotlight Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Spotlight Therapeutics is headquartered in Hayward, United States. It is registered at Hayward, California, United States.
Spotlight Therapeutics is a funded company, having raised a total of $80.67M across 5 funding rounds to date. The company's 1st funding round was a Series A of $7.27M, raised on Jan 2018.
Spotlight Therapeutics has 32 employees.
Founded in 2017 and based in Hayward, United States, the company focuses on biotechnology in the oncology sector. Cancer therapeutics are developed through a proprietary platform called TAGE, by which CRISPR nuclease effectors are delivered to selected cells in vivo. A pipeline is maintained for applications in immuno-oncology, hematology, and ophthalmology, with operations centered on advancing gene editing technologies for therapeutic use.
Spotlight Therapeutics's top competitors include Hummingbird Bioscience, Lyell Immunopharma and eGenesis.
Spotlight Therapeutics has 6 investors. Key investors include HHS, EPIQ, GordonMD Global Investments, Magnetic Ventures, and Google Ventures.
Spotlight Therapeutics operates through Spotlight Therapeutics Inc.